CIOs Face Competing and Complex Priorities in 2021, Finds New Snow Software Report
Snow Software, the global leader in technology intelligence, today released the 2021 IT Priorities Report, a comprehensive look at the issues and trends driving next year’s technology agenda. Aligning surveys of 1,000 IT leaders and 3,000 workers in the United States, United Kingdom, Germany and Australia found that while Covid-19 has created new concerns and deepened traditional challenges for IT, organizations with complete insight and governance of their technology ecosystem are better positioned to achieve their priorities.
In fact, mature technology intelligence – defined as the ability to understand and manage all technology resources – correlated to resilience and growth. Of the IT leaders classified as having mature technology intelligence, 79% were confident in their organization’s ability to weather current events and 100% indicated that innovation continues to be a strategic focus for their organization.
“IT teams around the world had to contend with extraordinary challenges this year due to the impact of Covid-19,” said Alastair Pooley, Chief Information Officer at Snow. “The complexities, risks and budget concerns IT departments traditionally face have been exacerbated, and a rapid acceleration of digital transformation and cloud adoption has brought new issues to the forefront. Now more than ever, IT leaders need to be in a position to quickly adapt to these macro trends as they define their top technology priorities in 2021.”
Key findings include:
- Technology management has become increasingly difficult. Many IT leaders indicated increases in technology spend across the board – on software, hardware, SaaS and cloud – over the past 12 months. Faced with more complex ecosystems, it is no surprise that 63% also reported technology management had become more difficult. As anticipated budget restrictions go into effect for 2021, IT leaders will need to demonstrate the value of their investments and ensure proper governance over their entire technology stack.
- Employee perception of IT has improved, but differing perceptions on technology management and procurement hint at potential issues. While 41% of workers believe that access to technology has improved, there remains a 22-point gap between IT leaders and employees on how easy it is to purchase software, applications or cloud services. This is not the only area where IT leaders and workers have varying views. Though they agree that security is the number one issue caused by unmanaged and unaccounted for technology, awareness of additional issues drops dramatically after that, with 16% of workers believing it causes no business issues whatsoever. The data suggests continued challenges ahead for organizations as they try to reduce risk across the board.
- Vendor audits are a looming but potentially underestimated risk in 2021. 87% of IT leaders said they had been audited by a software vendor over the last 12 months. The vendors that audited the most were Microsoft, IBM, Oracle, Adobe and SAP. Yet only 51% said they were concerned about audits over the next 12 months, an answer that varied wildly based on geography – 81% of US leaders said they were concerned compared to just 30% in Germany and 42% in the UK. Based on 2020 trends as well as vendor behavior following the 2008 recession, it appears European IT leaders are significantly underestimating this risk.
- Organization’s top IT priorities are inherently at odds with each other and often align with the IT department’s biggest challenges. IT leaders reported that their organization’s top priorities in 2020 were adopting new technologies (38%), reducing security risks (38%), reducing IT spend (38%). They paralleled the biggest challenges IT leaders faced over the past 12 months with managing cybersecurity threats (43%), implementing new technologies (40%) and supporting remote work (39%). Juggling these conflicting and difficult priorities became even more complicated in light of Covid-19.
- Strong technology intelligence enabled IT leaders to more effectively tackle their top priorities and challenges. Just 14% of IT leaders met the bar for mature technology intelligence. This elite group outpaced other respondents in their ability to support digital transformation, reduce risk, enable employees and control spend.
“As we collectively look ahead to 2021, it’s more important than ever that CIOs and IT leaders strike the right balance between managing risk and remaining agile in the face of continued unpredictability,” said Pooley. “It is clear from the data that a comprehensive understanding of technology resources and the ability to manage them is a key differentiator. IT leaders can use the insights to endure challenging periods like the pandemic, as well as embrace innovation to drive future growth and resilience.”
For more information about the Snow Software 2021 IT Priorities Report or download your free copy, please visit: https://go.snowsoftware.com/2020_ITPrioritiesReport_LP-Download.html.
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201112005156/en/
Contact information
Julie Neumann
Snow Software
press@snowsoftware.com
+1 615 498 9650
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
